ASO Author Reflections: Fibrinogen and Albumin Score Validated as a Prognostic Factor to Refine the Treatment Strategy for Esophageal Cancer Patients

Satoru Matsuda; Hiroya Takeuchi; Hirofumi Kawakubo; Ryo Takemura; Yusuke Maeda; Yuki Hirata; Takuji Kaburagi; Tomohisa Egawa; Tomohiko Nishi; Masaharu Ogura; Taku Miyasho; Akihiko Okamura; Shuhei Mayanagi; Kazumasa Fukuda; Rieko Nakamura; Tomoyuki Irino; Norihito Wada; Yuko Kitagawa

doi:10.1245/s10434-020-09008-1

ASO Author Reflections: Fibrinogen and Albumin Score Validated as a Prognostic Factor to Refine the Treatment Strategy for Esophageal Cancer Patients

Satoru Matsuda, Hiroya Takeuchi, Hirofumi Kawakubo, Ryo Takemura, Yusuke Maeda, Yuki Hirata, Takuji Kaburagi, Tomohisa Egawa, Tomohiko Nishi, Masaharu Ogura, Taku Miyasho, Akihiko Okamura, Shuhei Mayanagi, Kazumasa Fukuda, Rieko Nakamura, Tomoyuki Irino, Norihito Wada, Yuko Kitagawa

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Pages (from-to)	886-887
Number of pages	2
Journal	Annals of Surgical Oncology
Volume	27
DOIs	https://doi.org/10.1245/s10434-020-09008-1
Publication status	Published - 2020 Dec

ASJC Scopus subject areas

Surgery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1245/s10434-020-09008-1

Cite this

Matsuda, S., Takeuchi, H., Kawakubo, H., Takemura, R., Maeda, Y., Hirata, Y., Kaburagi, T., Egawa, T., Nishi, T., Ogura, M., Miyasho, T., Okamura, A., Mayanagi, S., Fukuda, K., Nakamura, R., Irino, T., Wada, N., & Kitagawa, Y. (2020). ASO Author Reflections: Fibrinogen and Albumin Score Validated as a Prognostic Factor to Refine the Treatment Strategy for Esophageal Cancer Patients. Annals of Surgical Oncology, 27, 886-887. https://doi.org/10.1245/s10434-020-09008-1

Matsuda, S, Takeuchi, H, Kawakubo, H, Takemura, R, Maeda, Y, Hirata, Y, Kaburagi, T, Egawa, T, Nishi, T, Ogura, M, Miyasho, T, Okamura, A, Mayanagi, S, Fukuda, K , Nakamura, R, Irino, T, Wada, N & Kitagawa, Y 2020, 'ASO Author Reflections: Fibrinogen and Albumin Score Validated as a Prognostic Factor to Refine the Treatment Strategy for Esophageal Cancer Patients', Annals of Surgical Oncology, vol. 27, pp. 886-887. https://doi.org/10.1245/s10434-020-09008-1

@article{bfffc1a86a124f8b9463c4400f3272f4,

title = "ASO Author Reflections: Fibrinogen and Albumin Score Validated as a Prognostic Factor to Refine the Treatment Strategy for Esophageal Cancer Patients",

author = "Satoru Matsuda and Hiroya Takeuchi and Hirofumi Kawakubo and Ryo Takemura and Yusuke Maeda and Yuki Hirata and Takuji Kaburagi and Tomohisa Egawa and Tomohiko Nishi and Masaharu Ogura and Taku Miyasho and Akihiko Okamura and Shuhei Mayanagi and Kazumasa Fukuda and Rieko Nakamura and Tomoyuki Irino and Norihito Wada and Yuko Kitagawa",

note = "Funding Information: Yuko Kitagawa: Relevant financial activities outside the submitted work: Taiho Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, Yakult Honsha Co., Ltd, Daiichi Sankyo Company, Ltd, Merck Serono Co., Ltd, Asahikasei Co., Ltd, EA Pharma Co., Ltd, Otsuka Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd, Otsuka Pharmaceutical Factory Inc., Shionogi & Co., Ltd, Kaken Pharmaceutical Co., Ltd, Kowa Pharmaceutical Co., Ltd, Astellas Pharma Inc., Medicon Inc., Dainippon Sumitomo Pharma Co., Ltd, Taisho Toyama Pharmaceutical Co., Ltd, Kyouwa Hakkou Kirin Co., Ltd, Pfizer Japan Inc., Ono Pharmaceutical Co., Ltd, Nihon Pharmaceutical Co., Ltd, Japan Blood Products Organization Medtronic Japan Co., Ltd, Sanofi KK. Yuko Kitagawa received grants from Eisai Co., Ltd, Tsumura & Co., KCI Licensing, Inc., Abbott Japan Co., Ltd, and Fujifilm Toyama Chemical Co., Ltd. ",

year = "2020",

month = dec,

doi = "10.1245/s10434-020-09008-1",

language = "English",

volume = "27",

pages = "886--887",

journal = "Annals of Surgical Oncology",

issn = "1068-9265",

publisher = "Springer New York",

}

TY - JOUR

T1 - ASO Author Reflections

T2 - Fibrinogen and Albumin Score Validated as a Prognostic Factor to Refine the Treatment Strategy for Esophageal Cancer Patients

AU - Matsuda, Satoru

AU - Takeuchi, Hiroya

AU - Kawakubo, Hirofumi

AU - Takemura, Ryo

AU - Maeda, Yusuke

AU - Hirata, Yuki

AU - Kaburagi, Takuji

AU - Egawa, Tomohisa

AU - Nishi, Tomohiko

AU - Ogura, Masaharu

AU - Miyasho, Taku

AU - Okamura, Akihiko

AU - Mayanagi, Shuhei

AU - Fukuda, Kazumasa

AU - Nakamura, Rieko

AU - Irino, Tomoyuki

AU - Wada, Norihito

AU - Kitagawa, Yuko

N1 - Funding Information: Yuko Kitagawa: Relevant financial activities outside the submitted work: Taiho Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, Yakult Honsha Co., Ltd, Daiichi Sankyo Company, Ltd, Merck Serono Co., Ltd, Asahikasei Co., Ltd, EA Pharma Co., Ltd, Otsuka Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd, Otsuka Pharmaceutical Factory Inc., Shionogi & Co., Ltd, Kaken Pharmaceutical Co., Ltd, Kowa Pharmaceutical Co., Ltd, Astellas Pharma Inc., Medicon Inc., Dainippon Sumitomo Pharma Co., Ltd, Taisho Toyama Pharmaceutical Co., Ltd, Kyouwa Hakkou Kirin Co., Ltd, Pfizer Japan Inc., Ono Pharmaceutical Co., Ltd, Nihon Pharmaceutical Co., Ltd, Japan Blood Products Organization Medtronic Japan Co., Ltd, Sanofi KK. Yuko Kitagawa received grants from Eisai Co., Ltd, Tsumura & Co., KCI Licensing, Inc., Abbott Japan Co., Ltd, and Fujifilm Toyama Chemical Co., Ltd.

PY - 2020/12

Y1 - 2020/12

UR - http://www.scopus.com/inward/record.url?scp=85089090093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089090093&partnerID=8YFLogxK

U2 - 10.1245/s10434-020-09008-1

DO - 10.1245/s10434-020-09008-1

M3 - Comment/debate

C2 - 32761333

AN - SCOPUS:85089090093

SN - 1068-9265

VL - 27

SP - 886

EP - 887

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

ER -

ASO Author Reflections: Fibrinogen and Albumin Score Validated as a Prognostic Factor to Refine the Treatment Strategy for Esophageal Cancer Patients

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this